Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study
Authors' conclusion
In adults with T1D, liraglutide improved several cardiometabolic risk factors and insulin sensitivity, although no significant short-term effects on CIMT were observed. Larger long-term trials are needed to clarify its potential role in cardiovascular prevention in this population.
Study context
- Population
- Adults aged 15–60 years with T1D, suboptimal control, on basal-bolus insulin; median age 36 years, 57.1% women, baseline mean HbA1c 67 mmol/mol (8.3%), median diabetes duration 11 years
- Participants
- 35 adults
- Exposure
- Liraglutide 1.8 mg/day for 24 weeks, before vs after
- Outcome
- CIMT (high-resolution B-mode US)
- Follow-up
- 24 weeks
Methodological detailssingle-arm, pilot
- Single-arm
- Pilot
Main finding
As reported in the abstract
CIMT, baseline vs 24 weeks
Liraglutide did not significantly modify carotid intima-media thickness (CIMT) (mm)
0.54 vs. 0.58 mm
p = 0.151
Baseline CIMT (mean ± SD)
0.54 ± 0.13 mm
Observational data: associations, not effects.
Further findings
Cardiometabolic risk factors and insulin sensitivity, baseline to 24 weeks
- Waist circumference
- 82.5-79 cm; p = 0.004
- Body weight
- 70-66.7 kg; p < 0.001
- BMI
- 25.5-24.3 kg/m²; p < 0.001
- Triglycerides
- 94-75 mg/dL; p = 0.02
- eGDR
- 7.9-8.9 mg/kg/min; p = 0.003
- Significant improvements
HbA1c · 12 and 24 weeks
- HbA1c improved at 12 weeks but was not sustained at week 24
Safety
- No severe hypoglycaemia, DKA, emergency visits or hospitalizations occurred
Original publication
Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study. Diabet Med. Published 15 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →